ASP Isotopes Inc. (ASPI) AI Stock Analysis

ASP Isotopes Inc., based in Boca Raton, Florida, specializes in the advancement and commercial application of isotopes, primarily focusing on Molybdenum-100 and Uranium-235. Established in 2021, the company develops Molybdenum-100 as a non-radioactive isotope used in the medical industry for healthcare imaging and diagnostics. It also develops Uranium-235, an isotope critical for nuclear energy production and carbon-free energy initiatives. The company operates in the Specialty Chemicals industry within the Basic Materials sector, employing 271 people.

ASP Isotopes reported FY2025 revenue of $23.8M, up 475.5% from $4.1M in FY2024 and $433,026 in FY2023. Gross margin compressed to 14.3% in FY2025 from 38.6% in FY2024 and 32.1% in FY2023. Operating margin was -239.8% in FY2025, while net losses expanded to -$175.1M, representing an EPS of -$1.71. In the latest quarter ended June 30, 2026, quarterly revenue grew 327.6% year-over-year, bringing trailing twelve-month revenue to $30.9M with an operating margin of -667.5% and an EPS of -$1.49.

As of June 30, 2026, ASP Isotopes held $254.9M in cash and short-term investments against $269.6M in total debt, resulting in net debt of $14.7M. The current ratio stood at 3.87, and shareholders' equity was $264.7M, giving a debt-to-equity ratio of 1.02. For FY2025, operating cash flow was -$37.8M and capital expenditures were $9.7M, leading to free cash flow of -$47.4M. The company's share count increased 291.3% over five years.

ASP Isotopes trades at a forward P/E of 54.3x, compared to 13.4x for the median of its US-listed Basic Materials peers. Its price-to-sales multiple is 10.6x versus the peer group median of 1.8x, and its enterprise value of $476.9M represents an EV-to-revenue multiple of 15.5x. Over the past year, ASPI shares fell 80.6%, underperforming the S&P 500 (SPY), which gained 16.8%. The stock also trades 57.9% below its 200-day moving average.

Wall Street coverage includes 3 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $13.00, representing a 507.5% premium over the last close of $2.14. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $19.9M and an EPS of -$0.70. For the following fiscal year, 2 analysts project revenue of $57.8M, representing 189.7% growth. Over the last 4 quarters, the company beat EPS estimates twice. The next earnings date is November 18, 2026.

This page is an AI-written research summary of ASP Isotopes Inc. (ASPI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ASPI income statement, ASPI balance sheet, ASPI key metrics, ASPI analyst forecast, ASPI chart. See the ASPI stock overview for the latest quote and news.